New depression pill NH102 shows promise in Mid-Stage trial
NCT ID NCT06842992
First seen Jan 08, 2026 · Last updated May 05, 2026 · Updated 18 times
Summary
This study tested a new medicine, NH102, for people with major depression. It included 243 adults aged 18 to 65. The goal was to see if NH102 reduces depression symptoms better than a placebo or an existing drug called duloxetine. Researchers measured changes using a standard depression rating scale.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER (MDD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Mental Health Center
Shanghai, China
Conditions
Explore the condition pages connected to this study.